The Quantellect read.As of Nov 19, 2026, 4 active firms cover Kalvista Pharmaceuticals Inc: 2 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $27.00 to $42.00, a moderate spread. The average target of $33.25 sits 23% above the current $27.00. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral250%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$33.25
+23.1% upside
Average target across 4 active firms as of Nov 19, 2026 vs $27.00 current
Highest Target$42.00
Average Target$33.25
Lowest Target$27.00
Detailed analyst forecasts for KALV
Showing 1–5 of 5 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 2 of 4 active firms rate KALV a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
Top analysts covering Kalvista Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KALV.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Neutral
No targeton KALV
Overall win rate
43%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Neutral
$27.00+0.0% to target
Overall win rate
45%
+ Follow
#3
Serge Belanger
Needham · Rank #129
Neutral
No targeton KALV
Overall win rate
46%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Neutral
$27.00+0.0% to target
Overall win rate
36%
+ Follow
#5
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton KALV
Overall win rate
35%
+ Follow
KALV stock forecast FAQ
What is KALV's average 12-month price target?+
The 4 active firms with a live target average $33.25 for Kalvista Pharmaceuticals Inc over the next 12 months, ranging from a $42.00 high to a $27.00 low, as of Nov 19, 2026.
Is KALV stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KALV?+
The Street-high target is $42.00 (Stifel), and the Street-low is $27.00 (HC Wainwright & Co.). The average of all 4 active-firm targets is $33.25.
How many active Wall Street firms cover KALV?+
4 active firms have a recognized rating on Kalvista Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KALV?+
Among analysts who currently cover KALV, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Neutral.
Have analysts been upgrading or downgrading KALV lately?+
As of Nov 19, 2026, 2 of 4 active firms rate KALV a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KALV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.